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The cDNA encoding lipocortin-like 39 kDa protein in guinea pig neutrophils was cloned into a yeast expression vector 
and the constructed plasmid was introduced into a yeast. The gene was expressed in an eukaryotic ell, yeast Saccharomp 
ces cerevisiae and the recombinant protein was purified and characterized. The purified protein was identical with the 
native one with respect o the antigenicity and several biochemical properties, such as inhibitory action against phospho- 
lipase 4, Ca Z+-dependent binding to acidic-phospholipids and F-actin and availability as a substrate for tyrosine kinase 
(EGF receptor/kinase) and protein kinase C. 
Lipccortin; Recombinant protein; Neutrophil; Protein kinase 
1. INTRODUCTION 
Lipocortins are a family of calcium-dependent 
phospholipid-binding proteins that inhibit PLA2 
[l-3]. The 39K in guinea pig neutrophils, which 
was previously designated as p33 [4-71, is also a 
family of lipocortins: the 39K specifically localizes 
in the cytoplasm of the resting neutrophils, 
translocates from cytoplasm to the inner surface of 
plasma membranes of activated neutrophils [5], in- 
hibits degradation of membranous phospholipids 
by PLA2, binds to muscle actin under certain con- 
ditions [6], and is phosphorylated by PKC [8]. 
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Analysis of the cDNA for 39K revealed an ex- 
tremely high homology with the cDNA for lipocor- 
tin I from human U937 cells [9] and from the lung 
of rodents [lO,ll]. 
Wallner et al. [9] reported that human recombi- 
nant lipocortin I inhibited the catalytic activity of 
PLA2. Moreover, Cirino et al. [12-141 reported 
that the recombinant lipocortin I inhibited the pro- 
duction of prostacycline and thromboxane AZ by 
human endothelial cells and guinea pig lung, 
respectively, and suppressed the carrageenin- 
induced paw edema of the rat. Since the recombi- 
nant protein is the product from procaryotic, 
Escherichia cob, its N-terminal residue, glycosyla- 
tion and the mode of processing may not be iden- 
tical with those of native lipocortin I. The present 
work describes the construction of a high expres- 
sion vector of recombinant 39K protein in an 
eukaryotic cell, yeast Saccharomyces cerevisiae, 
and a simple and efficient method for purification 
of the recombinant 39K. We also demonstrate that 
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the biological properties of the recombinant pro- 
tein are identical with those of native one. 
2. MATERIALS AND METHODS 
2.1. Materials 
Conventional enzymes were obtained from Toyobo Co., Ltd 
(Osaka) and Takara Shuzo Co., Ltd (Kyoto). Mono P column, 
polybuffer 96 and polybuffer 74 were obtained from 
Pharmacia-LKB (Uppsala); TSK gel G-3000SW column from 
Toyo Soda; [3H]oleic acid (8.9 Ci/mmol) from New England 
Nuclear (Dreieich); EGF from Funakoshi Co., Ltd (Tokyo); 
PLAr from Boehringer Mannheim (Mannheim). All other 
chemicals used were of analytical grade. 
2.2. Construction of expression plasmid 
As previously reported [7], we obtained hgpL8 and AgpL7 
cDNA clones, each containing the 5 ’ -terminal and 3 ’ -terminal 
region of 39K cDNA. In this study, we also used hgpL9, which 
contains the 5 ‘-terminal region (fig. 1A). These cDNA clones 
were subcloned into the EcoRI site of pUC9 and designated 
respectively pGPL8, pGPL7 and pGPL9. Each of the 0.4 kb 
EcoRI-HhaI fragment from pGPL8, the 0.2 kb HhaI-Bg/II 
fragment from pGPL9 and the 0.8 kb Bg/II-Sa/I fragment from 
pCPL7 were ligated with the 8 kb EcoRI-Safl fragment of 
pYHCClO1, which was a yeast expression vector described in 
(151 and the resultant plasmid was designated as pYGPLlO0 
(fig.lB). In plasmid pYGPL100, guinea pig neutrophil 39K 
cDNA was regulated by a glyceraldehyde-3-phosphate 
dehydrogenase (GAP) promoter, which is known to be a strong 
promoter in yeast [16]. 
2.3. Yeast strains and media for yeast 
The strain of Saccharomyces cerevtiiae used in this experi- 
ment was EH-13-1.5 (MAT, a, trpl) [17]. Transformation of the 
yeast was carried out by the method of Ito et al. [18]. Yeast 
strains containing pYGPLlO0 were grown at 30°C for 40 h in 
Burkholder’s medium [ 191. 
2.4. Purification of recombinant 39K 
The strain EH-13-15 containing pYGPLlO0 was cultivated at 
A) 
39 K cDNA 
I 1 hgPL8 
I I UPL7 
t I MPL 9 
Fig.1. Construction of a vector for expressing 39K cDNA in yeast. (A) Restriction map of 39K cDNA’s overlapping cDNA clones. 
The coding sequence is indicated by thick box. (B) pYHCClO1 was described in [15]. The solid boxes denote 39K cDNA. POAP, 
promoter of glyceraldehyde-3-phosphate dehydrogenase; Ap, ampicillin resistance; E, EcoRI; B, BgnI; H, HhaI; S, SalI. 
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30°C in Burkholder’s medium. About 40 g of cells were obtain- 
ed from a 7 1 broth. The yeast cells, which were suspended in 
50 ml of 50 mM Tris-HCI (pH 7.5) containing 5 mM EGTA, 
1 mM PMSF, and 0.01% leupeptin, were disrupted with bead 
beader (Biospeck products) at 4°C. The resulting lysate was 
centrifuged at 5000 x g at 4OC for 30 min. This supernatant was 
further incubated with 6 mM CaC12 at 4°C for 30 min and cen- 
trifuged at 100000 x g at 4’C for 60 min. The supernatant was 
removed and the pellet was suspended in 20 mM Hepes-KOH 
(pH 7.4) containing 0.1 M KCI, 25 mM EGTA, 1 mM PMSF, 
0.01% leupeptin at 4°C for 30 min. This suspension was cen- 
trifuged at 100000 x g at 4°C for 60 min. The following pro- 
cedure is the same as that described previously 161. Briefly, to 
concentrate the protein in the supernatant, solid m%)2so4 was 
added with constant stirring to a final saturation level of 100%. 
The mixture was allowed to stand overnight at 4”C, and cen- 
trifuged at 100000 x g for 60 min. The pellet was dissolved in 
. . volume (less than 10 ml) of 25 mM 
~iet~~~~*e-imin~iacetic acid (PH 8.3) (buffer A) and 
dialyzed overnight vs two 1-l volumes of buffer A. After 
dialysis, insoluble material was precipitated by centrifugation at 
10000 x g for 30 min. The supernatant was then loaded onto 
a Mono P column (200 x 5 mm) previously equilibrated with 
buffer A. Proteins were eluted with the elution buffer B (10% 
polybuffer-iminodiacetic acid, pH 5.0) at a flow rate of 
1.0 mb’min. The resulting fractions were analyzed by 12% 
SDS-PAGE. The 39Krich fraction was loaded onto a column 
(300 x 5 mm) of TSK gel G-3000SW previously equilibrated 
with 20 mM Hepes-KOH, 0.1 M KC1 buffer (pH 7.4) and pro- 
teins were eluted with the same buffer at a flow rate of 
0.5 ml/min. 
2.5. Determination of PLAz activity 
Samples were tested for PLAz inhibitory activity by an in 
vitro assay using [3H]oleic acid-labeled E. coli membranes as 
described by Davidson et al. [20]. 
2.6. Binding of F-actin 
The binding activity of 39K to F-actin was determined by the 
method of Hayashi et al. [21]. 
2.7. Phosphorylation of 39K by PKC 
Phosphorylation of 39K by PKC was routinely assayed by 
measuring the incorporation of “P from I?-‘*P]ATP into 39K 
at 30°C for 3 min by the method of Boni and Rondo [22]. The 
reaction mixture was subjected to SDS-PAGE and the gels were 
stained with Coomassie brilliant blue R250 (CBB). Then, 
autoradiograms of the 32P-labeled proteins were obtained as 
described previously [23]. 
2.8 EGF-dependent ph~pho~iat~on 
A-431 cells were grown in 75 cm2, culture flask containing 
Dulbecco’s modified Eagle’s medium (Flow Laboratories) sup- 
plemented with 10% fetal bovine serum, streptomycin and 
penicillin. The membrane fraction of the culture cells was ob- 
tained as described by De et al. 1241. Briefly, the reaction mix- 
tures contained in a final volume of 60 81, 20 mM Hepes (pH 
7.4), 2 mM MgClz, IO PM sodium vanadate, 15 fiCi 
Iy-32P]ATP and aliquots of the A-43 1 total particulate fraction. 
The reaction tubes containing all components except the ATP 
were placed on ice and preincubated for 10 min at 0°C in the 
absence or the presence of ECF (2 pg/ml). The reaction was in- 
itiated by adding 32P-labeled ATP. After 10 min of incubation 
at O”C, the reaction was terminated by adding 30 ~1 of the stop 
solution containing lO’J/‘o f SDS and heating for 3 mm at 
100°C. 
3. RESULTS AND DISCUSSION 
3.1. Purification of recombinant 39K 
A yeast transformant containing pYGPLlO0 
was cultivated in Burkholder’s medium for 40 h at 
30°C. The organisms were collected by centrifuga- 
tion and disrupted by bead beader. The crude 
samples were extracted by Ca’+-dependent 
precipitation. When these extracts were applied to 
the Mono P column, most of the 39K was eluted 
at pH 7.8 (fig.2, lane 5). The 39K-enriched frac- 
tions were pooled and subjected to TSK gel 
G-3000SW column chromatography. As shown in 
fig.2, lane 6, 39K was highly purified by this 
method: the purified protein migrated as a single 
band in SDS-PAGE with a molecular weight of 
35000. Immunological identity of native and the 
recombinant 39K was confirmed by immunoblot- 
Fig.2. SDS-PAGE analysis of recombinant 39K at different 
steps of purification. Samples were analyzed by 12% SDS- 
PAGE and stained by Coomassie brilliant blue. Lanes: 1, total 
lysate of yeast (control); 2, total lysate of yeast containing 
pYGPL100; 3, post-nuclear fraction; 4, a protein fraction 
which bound to membranes Ca’+-dependently; 5, Mono P 
fraction; 6, TSK gel G-3000SW fraction. 
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Fig.3. SDS-PAGE and Western blotting of total lysate of yeast 
and purified recombinant 39K. (A) Coomassie brilliant blue 
stain; (B) electroblotted onto Durapore filter and 
immunost~ned with mouse antiserum against native 39K. 
Lanes: 1, total lysate of yeast (control); 2, total lysate of yeast 
cont~ning pYGPL100, 3, purified recombinant 39K. 
RECOMBINANT 39Kfyg) 
Fig.4. Inhibition of PLAz by recombinant 39K. Aliquots of the 
purified recombinant 39K were preincubated with 50 ng porcine 
pancreatic PLAz (0) or ‘H-labeled E. coli membranes (x) at 
4°C for 10 min. The reaction was initiated by adding ‘H- 
labeled E. co/i membranes (0) or 50 ng porcine pancreatic 
PLAz (x) at 4’C and terminated 5 min later by adding 100,ul 
of 2 N HCI and 100 mg/ml of bovine serum albumin. After 
centrifugation to remove E. coli membranes, the radioactivity 
in the supernatant fraction was determined in a liquid 
scintillation spectrometer. 
SPSPSPSP 
43K+ 
39K-, 
c$ - - + + - - + + 
1OOmM I<’ - - - - + + + + 
Fig.5. Binding of F-actin to recombin~t 39K. The purified 
recombinant 39K was incubated with muscle F-actin for 1 h at 
25°C in the buffer solutions containing 1 mM CaC12 (+) or 
1 mM EGTA (-) in the presence (+) or absence (-) of 100 mM 
KCl. Then, the incubated samples were centrifuged and the 
supernatant (S) and the precipitates (P) were analyzed by SDS- 
PAGE and CBB staining. 
ting with antibody against native 39K (fig.3). The 
N-terminal amino acid sequence of purified recom- 
binant 39K was blocked as well as native one [6]. 
3.2. In~i~iti~~ of PLA2 activity by recombinant 
39K 
Previous studies in this laboratory [6] revealed 
A 8 
TRL, T R L / ,T R L,,T R L, 
-Co” *ca* -Cd+ *Ca* 
Fig.6. Autoradiograms of the phosphorylated recombinant 39K 
by PKC. Recombin~t 39K was incubated in the medium 
containing dipalmitoylphosphatidylcholine/cholesterol/phos- 
phatidylserine liposome (2: 1: 1 in molar ratio), 100 nM PMA 
and [r3’P]ATP in the presence or absence of Ca*+ for 30 min 
at 30°C. Free and membrane bound proteins were separated by 
Ficoil density gradient c~trifugation (flotation method) [4]. 
Proteins were analyzed by 12% SDS-PAGE and silver staining 
(A). Phosphorylated proteins were analyzed by autoradio- 
graphy (B). T, total protein fraction; R, unbound protein 
fraction; L, membrane-bound protein fraction. + Ca+*, 
0.3 mM Cat’* f - Ca+ -, 1 mM EGTA. 
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that native 39K inhibited PLA2 as did lipocortin I 
[2,3]. Thus, the PLAz inhibitory activity of the 
purified recombinant 39K was tested. Fig.4 shows 
that recombinant 39K inhibited the PLA2 activity 
as measured by j3H]oleic acid release from 
bacterial membranes. The inhibitory activity of 
recombinant 39K was slightly higher when prein- 
cubated with bacterial membranes than when 
preincubated with PLA2. These results suggested 
that 39K might interact with substrate phospho- 
lipids rather than with the enzyme. Davidson et al. 
[ 181 recently proposed that lipocortins might in- 
hibit PLAz activity by masking the surface of 
phospholipid membranes. This concept is also sup- 
ported by the study using sedimentation eouili- 
brium analysis [25]1 
present experiments 
proposal. 
The results obtained iu the 
are also consistent with this 
EGF -+ - + 
R39K - - * + 
B 
3.3. Binding of F-a&in 
Since the naturally occurring 39K binds to F- 
actin, the binding activity of the recombinant 39K 
to F-actin was also measured. In the presence of 
Ca2+ the recombinant 39K bound to F-actin a 
K”-free medium. However, EGTA inhibited the 
binding either in the presence or absence of Kf 
(fig.5). Thus, recombinant 39K also binds to F- 
actin by a Ca2+-dependent mechanism as did 
native 39K. 
3.4. Substrate for PKC or tyrosine kinase 
Lipocortin I has been shown to be phosphory- 
lated either by PKC [26,27] or EGF receptor/ 
kinase (tyrosine kinase) [28,29]. Previous studies 
revealed that the native 39K was also phosphor- 
ylated by PKC f8]. Thus, we tested whether the 
recombinant 39K also serves as a substrate for 
EGF + + + + 
-II 
&a* -Ca* 
B 
s F s P 
-1) 
+Ca* -Ca* 
Fig.7. EGF-dependent phospho~lation of 39K. (I) A-431 cells were grown at 37°C in DuIbecco’s modified Eagle’s medium 
supplemented with 10% fetal calf serum. In vitro phospho~Iation reactions using isolated A-43I cell membranes were analyzed by 
SDS-PAGE (A) and the radioactive products were visualized by autoradio~aphy (B). EGF, epidermal growth factor; R39K, 
recombinant 39K (200 pg/ml); M, molecular marker. (II) After phospho~lation by EGF receptor kinase with or without Ca’+, the 
recombinant samples were centrifuged at 10000 x g for 10 min at 4°C. Each of the supematant (S) or precipitant (P) fraction was 
analyzed by 12% SDS-PAGE (A) and the radioactive products were visualized by autoradiography (B). + Ca+ +, 0.5 mM CaC12; 
- Ca’ +, 1 mM EGTA. 
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PKC or EGF receptor/kinase. As shown in figs 6 
and 7, in the presence of Ca2+, the recombinant 
39K bound to liposomal and native membranes. 
Thus, only when associated with the membranes, 
recombinant 39K was phosphorylated by PKC and 
tyrosine kinase (fig.6, fig.711). Fava et al. [28] and 
Cohen et al. [30] have also reported that Ca*+ is re- 
quired for the binding and phosphorylation of the 
35 kDa protein (lipocortin I) isolated from A-431 
cells by membrane or endosome preparation deriv- 
ed from the same cells. The membrane-binding ac- 
tivity of recombinant 39K remained unchanged 
after phosphorylation by PKC (fig.frL) or EGF 
receptor/kinase (fig.711). 
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